Back

Optimization of a liver Trm cell-inducing mRNA vaccine by reduction of type I interferon response

Minnell, J. J.; Ganley, M.; Lee, A. R.; Phabmixay, T.; Farrand, K. J.; Burn, O. K.; Mamum, J. C.; Lamb, E.; Draper, S. L.; Chan, S. T. S.; Palmer, O. R.; Mason, N. C.; Bilbrough, T.; Anderson, R. J.; Compton, B. J.; Cozijnsen, A.; McKenzie, R. E.; Vink, J. N. A.; Le, S.; Jayasinghe, D.; Gras, S.; McFadden, G. I.; Heath, W. R.; Beattie, L.; Painter, G. F.; Holz, L. E.; Hermans, I. F.

2026-05-12 immunology
10.64898/2026.05.07.723643 bioRxiv
Show abstract

CD8+ tissue-resident memory T cells provide rapid frontline protection at pathogen invasion sites, making them attractive targets for vaccine-mediated immunity. We previously developed an NKT cell-adjuvanted mRNA lipoplex vaccine capable of inducing liver Trm cells and sterile protection against malaria in mice. Here, we show that type I interferon (IFN-I) signalling through dendritic cells -- not T cells -- is a key brake on liver Trm induction by this vaccine. Optimising mRNA manufacturing to reduce immunostimulatory contaminants substantially dampened IFN-I production, boosted antigen expression in the lymphoid tissues, and drove significantly greater Trm accumulation. These enhanced responses translated into superior protection against parasite challenge. Our findings identify DC-intrinsic IFN-I signalling as a tractable target, and mRNA manufacturing quality as a critical and underappreciated lever, for maximising Trm-based vaccine efficacy.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.